Cargando…
Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer
Although TC2N has proven to be an oncogene in lung cancer, its biological function and molecular mechanisms in other cancer still remains unclear. Here, we investigate in breast cancer that TC2N expression is sharply overexpressed in breast cancer specimens compared with normal breast specimens, and...
Autores principales: | Hao, Xiang-lin, Gao, Li-yun, Deng, Xiao-juan, Han, Fei, Chen, Hong-qiang, Jiang, Xiao, Liu, Wen-bin, Wang, Dan-dan, Chen, Jian-ping, Cui, Zhi-hong, Ao, Lin, Cao, Jia, Liu, Jin-yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541591/ https://www.ncbi.nlm.nih.gov/pubmed/31142739 http://dx.doi.org/10.1038/s41419-019-1663-5 |
Ejemplares similares
-
Author Correction: Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer
por: Hao, Xiang-lin, et al.
Publicado: (2019) -
TC2N, a novel oncogene, accelerates tumor progression by suppressing p53 signaling pathway in lung cancer
por: Hao, Xiang-lin, et al.
Publicado: (2018) -
Enhanced Antitumor Efficacy of Gemcitabine by Evodiamine on Pancreatic Cancer via Regulating PI3K/Akt Pathway
por: Wei, Wei-Tian, et al.
Publicado: (2011) -
MrgprF acts as a tumor suppressor in cutaneous melanoma by restraining PI3K/Akt signaling
por: Shen, Qiushuo, et al.
Publicado: (2022) -
SKA3 promotes lung adenocarcinoma metastasis through the EGFR–PI3K–Akt axis
por: Hu, Dan-dan, et al.
Publicado: (2020)